Genetic test to prevent child deafening being implemented in England

A new test called Genedrive System to detect babies at risk of gentamycin-related deafness was developed at the University of Manchester, funded by the National Institute for Health Research (NIHR). On April 02, 2022, NHS England and NHS Improvement announced that Genedrive is now fully CE certified to be used in a clinical setting.

The test takes 25 minutes to identify whether a critically ill baby admitted to intensive care has a gene that could result in permanent hearing loss if they are treated with a common emergency antibiotic (gentamycin). The cost of the test is £80 per child.

The test is expected to be implemented in routine care in all NHS Manchester Foundation Trust hospitals within several weeks.

Following the ground-breaking study, the NHS Genomic Medicine Service Alliance and the NHS will explore how this technology can be launched as part of a clinical service through the NHS Genomic Medicine Service.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).